FULC
Fulcrum Therapeutics·NASDAQ
--
--(--)
--
--(--)
4.84 / 10
Netural
Fund flow analysis shows a good score (7.63/10) with positive Small-scale inflows (0.502) but negative Medium- and Large-scale trends. This indicates short-term money is entering, yet larger institutions are stepping back, aligning with the overall neutral price trend. Coupled with an overwhelmingly bullish analyst consensus (Strong Buy 50%, Buy 25%), the data suggest that retail or nimble funds are driving activity while bigger players remain cautious.
Fund Flow Rating
Analyst RatingStrong Buy
Wall Street Opinions
Strong Buy
Strong Buy
50%
Buy
25%
Hold
0%
Sell
13%
Strong Sell
0%
Date2025-12-08
InstitutionHC Wainwright & Co.
Times predicted3
Historical Win Rate33.3%
What is the analyst consensus for FULC?
- FULC holds a Bearish analyst rating, with 50% of experts assigning a Strong Buy grade. Factoring in net Outflows from order flow data, the comprehensive Sentiment Score stands at 4.84/10 (Netural).
